Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedApr 16, 2026
DataAggregated Company Financials
Companies181
  • 7D2.3%
  • 3M0.9%
  • 1Y4.0%
  • YTD0.1%

In the last week, the Pharma industry is up 2.3%, with Zydus Lifesciences up 4.1%. This means that the industry has gained 4.0% over the past year. Looking forward, earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 16 Apr 2026₹20.4t₹4.3t₹621.0b27.8x32.9x4.7x
Sat, 14 Mar 2026₹20.3t₹4.3t₹621.2b25.1x32.7x4.7x
Mon, 09 Feb 2026₹19.8t₹4.3t₹616.1b27.6x32.2x4.6x
Wed, 07 Jan 2026₹20.7t₹4.2t₹613.3b28.9x33.7x4.9x
Fri, 05 Dec 2025₹20.6t₹4.2t₹612.9b29.2x33.7x4.9x
Sun, 02 Nov 2025₹20.2t₹4.1t₹594.9b29.9x33.9x4.9x
Tue, 30 Sep 2025₹19.8t₹4.1t₹588.1b29.7x33.6x4.9x
Thu, 28 Aug 2025₹20.1t₹4.1t₹589.1b29.8x34.2x5x
Sat, 26 Jul 2025₹20.9t₹4.0t₹595.0b32.8x35.1x5.2x
Mon, 23 Jun 2025₹19.9t₹4.0t₹595.3b31.5x33.5x5x
Wed, 21 May 2025₹19.5t₹4.0t₹582.4b31.5x33.5x4.9x
Fri, 18 Apr 2025₹19.5t₹3.9t₹559.2b28.5x34.8x5x
Sun, 16 Mar 2025₹18.5t₹3.9t₹559.4b27x33.2x4.8x
Tue, 11 Feb 2025₹19.8t₹3.9t₹547.6b31.3x36.2x5.1x
Thu, 09 Jan 2025₹21.1t₹3.8t₹527.0b34.5x40.1x5.5x
Sat, 07 Dec 2024₹20.8t₹3.8t₹526.7b36x39.5x5.5x
Mon, 04 Nov 2024₹21.2t₹3.8t₹504.9b38.3x42.1x5.7x
Wed, 02 Oct 2024₹21.6t₹3.7t₹492.6b41.6x43.8x5.8x
Fri, 30 Aug 2024₹20.9t₹3.7t₹492.4b40.4x42.5x5.6x
Sun, 28 Jul 2024₹19.5t₹3.6t₹460.1b36.7x42.4x5.3x
Tue, 25 Jun 2024₹17.4t₹3.6t₹448.3b32.5x38.8x4.9x
Thu, 23 May 2024₹17.2t₹3.5t₹446.5b34.6x38.6x4.9x
Sat, 20 Apr 2024₹16.7t₹3.5t₹418.9b33.1x39.9x4.8x
Mon, 18 Mar 2024₹16.6t₹3.5t₹418.7b31.7x39.7x4.8x
Wed, 14 Feb 2024₹16.7t₹3.4t₹424.5b32.8x39.4x4.9x
Fri, 12 Jan 2024₹15.6t₹3.4t₹396.0b35.4x39.5x4.6x
Sun, 10 Dec 2023₹14.3t₹3.4t₹395.1b31.4x36.1x4.2x
Tue, 07 Nov 2023₹13.2t₹3.3t₹379.0b29.8x34.8x4x
Thu, 05 Oct 2023₹13.3t₹3.3t₹369.5b30x35.9x4.1x
Sat, 02 Sep 2023₹12.8t₹3.3t₹367.0b29.3x34.9x3.9x
Mon, 31 Jul 2023₹12.7t₹3.2t₹345.7b27.7x36.8x4x
Wed, 28 Jun 2023₹11.5t₹3.2t₹342.4b25.8x33.6x3.6x
Fri, 26 May 2023₹10.4t₹3.1t₹297.7b26.3x35.1x3.3x
Sun, 23 Apr 2023₹9.9t₹3.0t₹277.7b26.4x35.8x3.3x
Price to Earnings Ratio

35.8x


Total Market Cap: ₹9.9tTotal Earnings: ₹277.7bTotal Revenue: ₹3.0tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.5x202420252026
Current Industry PE
  • Investors are pessimistic on the Indian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 32.9x which is lower than its 3-year average PE of 36.5x.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 13% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market2.68%
Healthcare2.79%
Pharma2.26%
Pharma2.26%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ZYDUSLIFE Zydus Lifesciences₹939.104.1%
+₹37.1b		12.9%PE19.1x
AUROPHARMA Aurobindo Pharma₹1.39k3.4%
+₹26.8b		18.3%PE23.1x
LAURUSLABS Laurus Labs₹1.13k4.1%
+₹24.1b		79.7%PE72.2x
ALKEM Alkem Laboratories₹5.57k3.7%
+₹23.9b		12.5%PE28.1x
GLENMARK Glenmark Pharmaceuticals₹2.25k3.7%
+₹22.7b		67.6%PE59.6x

Latest News

GLENMARK
₹2,249.50
Glenmark Pharmaceuticals
7D
3.7%
1Y
67.6%

GLENMARK: Future US Respiratory Approvals Will Not Offset Earnings Risk

Analysts have adjusted their fair value estimate for Glenmark Pharmaceuticals slightly lower from ₹1,555.42 to ₹1,531.86, citing updated assumptions around revenue growth, profit margins, and future P/E valuation. What's in the News Received final U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg, deemed bioequivalent and therapeutically equivalent to Endometrin Vaginal Inserts, 100 mg, with the reference market showing approximately US$59.2m in annual sales for the 12 months ending February 2026 (IQVIA via company announcement).
GLAND
₹1,735.60
Gland Pharma
7D
-0.8%
1Y
19.7%
ZYDUSLIFE
₹939.10
Zydus Lifesciences
7D
4.1%
1Y
12.9%

ZYDUSLIFE: Diabetes And Obesity Launches And Oncology Biosimilars Will Shape A Balanced Outlook

Analysts have raised their price target on Zydus Lifesciences by about ₹2 to roughly ₹994 per share, reflecting slightly higher revenue growth assumptions, a modest tweak to long term profit expectations, and a small adjustment in the assumed future P/E multiple. What's in the News Zydus has launched Semaglutide injection in India under the brands SEMAGLYN, MASHEMA and ALTERME for Type 2 diabetes and obesity, using a reusable multi dose pen device priced at about ₹2,200 per month.
SUNPHARMA
₹1,693.10
Sun Pharmaceutical Industries
7D
-1.4%
1Y
-3.3%

SUNPHARMA: Obesity And Diabetes Launches Will Support A Constructive Outlook

Analysts have trimmed their price target for Sun Pharmaceutical Industries by about ₹5 to reflect slightly adjusted assumptions on fair value, revenue, profit margins, and future P/E expectations. What's in the News US FDA accepted a supplemental Biologics License Application for ILUMYA for adults with active psoriatic arthritis, with a regulatory action date expected by October 29, 2026, following prior approvals for multiple psoriasis indications and broad global authorizations (Product related announcement).
LAURUSLABS
₹1,128.35
Laurus Labs
7D
4.1%
1Y
79.7%
CONCORDBIO
₹1,037.40
Concord Biotech
7D
-1.6%
1Y
-39.8%

CONCORDBIO: Upcoming Board Review And Governance Changes Will Support Future Upside

Analysts have reduced their price target on Concord Biotech slightly from ₹1,426.67 to ₹1,414.17, reflecting modestly lower assumptions for revenue and profit margins, while keeping the discount rate and long-term P/E expectations broadly unchanged. What's in the News A board meeting is scheduled for Feb 11, 2026 at 17:00 Indian Standard Time to review and approve the standalone and consolidated unaudited financial results for the third quarter and nine months ended Dec 31, 2025, along with the limited review report from the statutory auditors (Key Developments).
AUROPHARMA
₹1,386.50
Aurobindo Pharma
7D
3.4%
1Y
18.3%

AUROPHARMA: Higher Margin Assumptions And Buybacks Will Shape A Balanced Outlook

Analysts have lifted their fair value estimate for Aurobindo Pharma to about ₹1,366 from roughly ₹1,293, citing model updates that reflect a lower discount rate, a higher projected profit margin of around 23%, and a slightly lower assumed future P/E multiple. Analyst Commentary Analysts looking at Aurobindo Pharma are focusing on how recent model tweaks, particularly around discount rates, profit assumptions, and valuation multiples, affect the risk and reward profile for shareholders.
ALKEM
₹5,570.00
Alkem Laboratories
7D
3.7%
1Y
12.5%

ALKEM: New Diabetes Franchise And Dividend Policy Will Shape Medium-Term Upside

Analysts have made a small trim to their fair value estimate for Alkem Laboratories, with the price target moving from about ₹5,920.71 to ₹5,911.29. This reflects updated views on discount rates, revenue growth, profit margins and future P/E assumptions.
COHANCE
₹362.95
Cohance Lifesciences
7D
14.5%
1Y
-68.9%

COHANCE: FDA Warning Letter Remediation Will Support Future Upside Potential

Analysts have trimmed their fair value estimate for Cohance Lifesciences from about ₹512.67 to roughly ₹507.11, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations. What’s in the News The U.S. FDA has issued Warning Letter No. 718812 to Cohance Lifesciences Limited regarding Current Good Manufacturing Practice (CGMP) violations at its Nacharam facility in Medchal Malkajgiri, Telangana, India (FDA / CDER).
MANKIND
₹2,104.40
Mankind Pharma
7D
2.4%
1Y
-18.5%

MANKIND: Upcoming Results And Solid Margins Will Support Further Upside

Analysts have cut their price target on Mankind Pharma by ₹30 to reflect slightly lower assumptions for revenue growth, profit margins and future P/E multiples, resulting in a modest reset in fair value expectations. What's in the News A board meeting is scheduled on Feb 3, 2026 at 15:00 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the Limited Review Report (Key Developments).
500420
₹4,156.35
Torrent Pharmaceuticals
7D
1.5%
1Y
27.7%

500420: New Metabolic Franchise And Dividend Plan Will Drive Future Upside

Analysts have lifted their price target on Torrent Pharmaceuticals slightly from about ₹4,499 to around ₹4,527, reflecting updated assumptions around revenue growth, profit margins and future P/E levels. What's in the News Torrent Pharmaceuticals launched its Semaglutide brands Sembolic and Semalix in India, offering both oral and injectable formulations that target metabolic disorders such as type 2 diabetes and obesity (Product announcement).
NATCOPHARM
₹1,086.80
NATCO Pharma
7D
-3.3%
1Y
31.3%

NATCOPHARM: Diabetes Partnership And New Launches Will Support Future Upside

Analysts have trimmed their price target on NATCO Pharma to ₹1,391.29, reflecting slightly softer assumptions on revenue growth and profit margins, along with a modestly higher future P/E multiple. What's in the News NATCO received Central Drugs Standard Control Organisation approval to manufacture and market generic Semaglutide injection in India, with a launch planned in March 2026 for adults with insufficiently controlled type 2 diabetes (CDSCO approval).
530549
₹411.25
Shilpa Medicare
7D
-1.9%
1Y
22.4%

530549: Committee Reconstitution And Earnings Review Will Support Future Upside Potential

Analysts have maintained the fair value estimate for Shilpa Medicare at ₹600. A slightly lower implied future P/E and minor adjustments to assumptions on the discount rate, revenue growth, and profit margins reflect updated views on the company’s risk profile and earnings quality.
506414
₹321.85
Fermenta Biotech
7D
-3.9%
1Y
17.2%
524774
₹2,255.05
NGL Fine-Chem
7D
-4.9%
1Y
113.8%
WOCKPHARMA
₹1,359.10
Wockhardt
7D
-0.8%
1Y
-3.9%